# Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

> **NCT01186705** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** MK-2206

## Key facts

- **NCT ID:** NCT01186705
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2015-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186705, "Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01186705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*